Quest for the right Drug
אנדרוג'ל 50 מ"ג ANDROGEL 50 MG (TESTOSTERONE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
בין-עורי : TRANSDERMAL
צורת מינון:
ג'ל : GEL
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects a. Summary of the safety profile The most frequently observed adverse drug reactions at the recommended dosage of gel per day were skin reactions at the application site, erythema, acne, dry skin. b. Tabulated list of adverse reactions Clinical trial data Adverse drug reactions reported in 1 - <10% of patients treated with this medicine in the controlled clinical trials are listed in the following table: Adverse effects have been ranked under headings of frequency using the following convention: very common (≥1/10);common (≥1/100; <1/10); uncommon (≥1/1,000;<1/100); rare (≥1/10,000;<1/1,000); very rare (<1/10,000); frequency not known (cannot be estimated from the available data). Adverse reactions - Preferred Term MedDRA Common adverse reactions (>1/100;<1/10) Organ system class Psychiatric disorders Mood disorders Dizziness, paraesthesia, amnesia, Nervous system disorders hyperaesthesia vascular disorders Hypertension Gastro-intestinal disorders Diarrhoea Skin and subcutaneous disorders Alopecia, urticaria gynaecomastia (which may be persistent, is a Reproductive and system and breast common finding in patients treated for disorders hypogonadism), mastodynia, Prostatic disorders General disorders and administration site Headache conditions Changes in laboratory tests (polycythemia, Investigations lipids), Haematocrit increased, Red blood cell count increased, Haemoglobin increased Post-marketing experience The following table includes adverse reactions identified during post-approval use of this medicine in addition to other known undesirable effects reported in the literature following testosterone oral, injectable or transdermal treatment. Adverse effects have been ranked under headings of frequency using the following convention: very common (≥1/10);common (≥1/100; <1/10); uncommon (≥1/1,000;<1/100); rare (≥1/10,000;<1/1,000); very rare (<1/10,000); frequency not known (cannot be estimated from the available data). MedDRA Adverse reactions – Preferred Term System Organ Frequency not Common Rare Very Rare Class known (cannot (≥1/100;<1/10) (≥1/10,000; (<1/10,000) be estimated <1/1,000) Prostate cancer Hepatic Neoplasms (Data on prostate neoplasm benign, cancer risk in malignant and association with unspecified testosterone (including therapy are cysts and inconclusive) polyps) Metabolism and Weight gain, nutrition electrolyte disorders changes (retention of sodium, chloride, potassium, calcium, inorganic phosphate and water) during high dose and/or prolonged treatment Psychiatric Nervousness, disorders depression, hostility Respiratory, Sleep apnoea thoracic and mediastinal disorders Hepatobiliary disorders Jaundice Skin and acne, subcutaneous seborrhoea, tissue disorders balding Musculoskeletal Muscle cramps and connective tissue disorders Renal and Urinary urinary obstructions disorders Reproductive Libido changes, system and increased Priapism, breast frequency of disorders erections; therapy with high doses of testosterone preparations commonly reversibly interrupts or reduces spermatogenesis, thereby reducing the size of the testicles; prostate abnormalities, General High dose or disorders and long-term administration administration of site conditions testosterone occasionally increases the occurrences of water retention and oedema; hypersensitivity reactions may occur. Because of the alcohol contained in the product, frequent applications to the skin may cause irritation and dry skin Investigations Haematocrit Liver function increased, test haemoglobin abnormalities increased, red blood cell count increased Reporting suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il/
שימוש לפי פנקס קופ''ח כללית 1994
Androgen deficiency states in men, breast cancer in women, aplastic anemia
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף